
Michael Mina
Chief Science Officer
eMed Labs Continue Reading Michael Mina
Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.
The future trajectory of the Covid-19 pandemic hinges on the dynamics of adaptive immunity against SARS-CoV2; however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future Covid-19 cases given different protective efficacy and duration of the adaptive immune response to SARS-CoV-2, as well as its interaction with vaccines and nonpharmaceutical interventions. We find that variations in the immune response to primary SARS-CoV-2 infections and a potential vaccine can lead to dramatically different immune landscapes and burdens of critically severe cases, ranging from sustained epidemics to near elimination. Our findings illustrate likely complexities in future Covid-19 dynamics, and highlight the importance of immunological characterization beyond the measurement of active infections for adequately projecting the immune landscape generated by SARS-CoV-2 infections.
Science (New York, N.Y.)

Chief Science Officer
eMed Labs Continue Reading Michael Mina

Associate Research Scholar
Princeton University Continue Reading Rachel Baker

Public Health Analytics & Modeling Fellow
U.S. Department of Health and Human Services Continue Reading Sinead Morris